Sildenafil, tadalafil, and vardenafil each competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accumulation and relaxation of vascular smooth muscle. Biochemical potencies (affinities) of these compounds for PDE5 determined by IC 50 , K D (isotherm), K D (dissociation rate), and K D ( 1 ⁄2 EC 50 ), respectively, were the following: sildenafil (3.7 Ϯ 1.4, 4.8 Ϯ 0.80, 3.7 Ϯ 0.29, and 11.7 Ϯ 0.70 nM), tadalafil (1.8 Ϯ 0.40, 2.4 Ϯ 0.60, 1.9 Ϯ 0.37, and 2.7 Ϯ 0.25 nM); and vardenafil (0.091 Ϯ 0.031, 0.38 Ϯ 0.07, 0.27 Ϯ 0.01, and 0.42 Ϯ 0.10 nM). Thus, absolute potency values were similar for each inhibitor, and relative potencies were vardenafil Ͼ Ͼ tadalafil Ͼ sildenafil. Binding of each 3 H inhibitor to PDE5 was specific as determined by effects of unlabeled compounds. 
H
Inhibitors did not bind to isolated PDE5 regulatory domain. Close correlation of EC 50 values using all three 3 H inhibitors competing against one another indicated that each occupies the same site on PDE5. Studies of sildenafil and vardenafil analogs demonstrated that higher potency of vardenafil is caused by differences in its double ring. Exchange-dissociation studies revealed two binding components for each inhibitor. Excess unlabeled inhibitor did not significantly affect 3 H inhibitor dissociation after infinite dilution, suggesting the absence of subunit-subunit cooperativity. cGMP addition increased binding affinity of [ 3 H]tadalafil or [ 3 H]vardenafil, an effect presumably mediated by cGMP binding to PDE5 allosteric sites, implying that either inhibitor potentiates its own binding to PDE5 in intact cells by elevating cGMP. Without inhibitor present, cGMP accumulation would stimulate cGMP degradation, but with inhibitor present, this negative feedback process would be blocked.
Phosphodiesterase-5 (PDE5) is 1 of 11 mammalian PDE families known to date . PDE5 is a cGMP-specific PDE and is abundant in most smooth muscle tissues as well as in platelets, gastrointestinal epithelial cells, and Purkinje cells of the cerebellum Shimizu-Albergine et al., 2003) . The enzyme was first identified, purified, and cloned in this laboratory (Lincoln et al., 1976; Francis et al., 1980; Thomas et al., 1990a; McAllister-Lucas et al., 1993) . PDE5 is a homodimer, and each monomer is a chimeric protein that is composed of a regulatory domain and a catalytic domain . The catalytic domain catalyzes the breakdown of cGMP to 5Ј-GMP, and the regulatory domain contains allosteric cGMP-binding sites and a phosphorylation site . Two tandem homologous repeats of ϳ110 amino acids each in the regulatory domain are termed GAF domains (a and b) because of their presence in cGMP-binding cyclic nucleotide PDEs, Anabaena adenylyl cyclase, and the bacterial transcription factor FhlA (Thomas et al., 1990a; McAllister-Lucas et al., 1993; Aravind and Ponting, 1997) . Isolated GAF a monomer binds cGMP with high affinity, but cGMP binding to GAF b has yet to be demonstrated (Liu et al., 2002) . Allosteric binding of cGMP to PDE5 regulatory domain increases affinity of the catalytic site for cGMP, thereby stimulating the rate of cGMP hydrolysis (Thomas et al., 1990b; Corbin and Francis, 1999; Okada and Asakawa, 2002; Corbin et al., 2003; Mullershausen et al., 2003; Rybalkin et al., 2003) . cGMP binding to the regulatory domain also stimulates phosphorylation of PDE5 at Ser-92 (bovine) by cGMP-dependent protein kinase in vitro and in vivo (Thomas et al., 1990b; Wyatt et al., 1998; Mullershausen et al., 2001; Murthy, 2001; Rybalkin et al., 2002) . It is presumed that cGMP binding to the regulatory domain produces a conformational change in PDE5 that exposes Ser-92. The resulting phosphorylation of PDE5 increases affinity of the regulatory domain for cGMP and increases catalytic activity as well (Corbin et al., 2000) . These effects suggest that PDE5 is critically involved in negative feedback regulation of cellular cGMP levels.
Several compounds that potently inhibit PDE5 have been synthesized recently, and three of these are now in clinical use for treatment of male erectile dysfunction. After sexual arousal, these inhibitors enhance accumulation of cGMP in the smooth muscle of the arteries supplying the penis and the sinusoids of the penile corpus cavernosum. Sildenafil (Viagra; Pfizer, New York, NY) was the first compound of this class to be marketed for the treatment of male erectile dysfunction. It also shows promise in the clinical treatment of ailments related to smooth muscle tissues, such as pulmonary hypertension (Weimann et al., 2000) . Newer PDE5 inhibitors that have the same therapeutic mechanism as sildenafil, such as tadalafil (Cialis; Lilly-ICOS, Bothell, WA), and vardenafil (Levitra; Bayer Corporation, West Haven, CT), have also been approved for use in many countries. The availability of these high-affinity inhibitors provides significant new tools for studies of the PDE5 catalytic domain. This laboratory recently examined some characteristics of the catalytic domain and its regulation by investigating [
3 H]sildenafil binding to the enzyme . The structures of tadalafil and vardenafil differ significantly from that of sildenafil, and these three compounds have differing inhibitory potencies. Molecular contacts of the three inhibitors within the catalytic site of the PDE5 have recently been revealed by X-ray crystallography (Sung et al., 2003 3 H]vardenafil. The availability of these compounds has allowed a thorough analysis of the interaction of these agents with PDE5, which is reported herein. These radiolabeled inhibitors have also permitted the most comprehensive, head-to-head comparison of potencies of these agents to bind to PDE5 using several approaches. Moreover, some novel features of the inhibitors and of PDE5 are uncovered using these approaches.
Materials and Methods

Materials. [
3 H]cGMP and DEAE-Sephacel were purchased from Amersham Biosciences Inc. (Piscataway, NJ). 3-Isobutyl-1-methylxanthine (IBMX), histone type II-AS, Crotalus atrox snake venom, 5Ј-GMP, and cGMP were obtained from Sigma Chemical Co. (St. Louis, MO). His-tagged, full-length recombinant bovine PDE5 was isolated from infected Sf9 cells using nickel/nitrilotriacetic acid agarose (QIAGEN, Valencia, CA) as described previously . Native bovine lung PDE5 was obtained and purified using Blue Sepharose described in an earlier report (Francis and Corbin, 1988; Thomas et al., 1990a) . Sildenafil was purified from Viagra tablets by following the method established previously in this laboratory . Purified sildenafil was submitted to Amersham Biosciences for radiolabeling with tritium. Tadalafil was synthesized according to Daugan (2000) . After confirming the compound structure by mass spectrometry, tadalafil was submitted to Amersham Biosciences for radiolabeling with tritium. High-performance liquid chromatography results from Amersham indicated that [ 3 H]sildenafil was Ͼ98% pure, whereas the [ 3 H]tadalafil preparation was Ͼ99% pure. Vardenafil, [ 3 H]vardenafil, demethyl-vardenafil, and methyl-sildenafil were provided by Bayer AG (Wuppertal, Germany). All three 3 H inhibitors that had been stored for more than a year were subjected to Sephadex G-25 chromatography, which adsorbs PDE inhibitors and provides high resolution Francis et al., 2003) . All three 3 H inhibitors were resolved in single peaks and coeluted with purified unlabeled inhibitors, suggesting that the 3 H inhibitors were unaltered after storage. Even so, it cannot be completely ruled out that the curvilinearity observed in the dissociation of 3 H inhibitors in Fig. 5 could be caused by slight structural heterogeneity of the inhibitors.
Isolated Regulatory Domain of PDE5. Residues Met1 to Glu539 of human PDE5 were amplified from the hPDE5 cDNA (courtesy of Tanabe Research Laboratories Inc., San Diego, CA). Using the forward primer RZMet1for (5Ј-GATATTGAATTCATGGAGCGGGCCGGC-CCCAGCT-3Ј) and the reverse primer RZGlu539rev (5Ј-GATGAT-AGCGGCCGCCTATCTCTTGTTTCTTCCTCTGCT-3Ј), containing EcoRI and NotI sites (underlined) and a stop codon (bold italic). The resulting PCR fragment (1649 base pairs) was cloned into pCR 2.1-Topo (Invitrogen, Carlsbad, CA) and verified by sequencing. The fragment was excised by digestion with EcoRI and NotI and was inserted into baculovirus transfer pAcHLT-A (BD PharMingen, San Diego, CA) digested with the same enzymes. The resulting plasmid was cotransfected with the BaculoGold baculovirus DNA (BD PharMingen) into Sf9 cells according to the manufacturer's instructions. The transfected cells were incubated at 27°C for 5 days. Afterward, 100 l of collected culture medium was used to infect 2 ϫ 10 7 freshly prepared Sf9 cells for viral amplification. The recombinant baculovirus was amplified two more times to obtain a high titer stock solution by infecting freshly seeded Sf9 cells. The infected cells were incubated at 27°C for 4 days before protein was harvested. Purification was carried out using nickel/nitrilotriacetic acid agarose as described previously .
PDE Assays. PDE activity was determined using a modified method (Martins et al., 1982) as described previously (Gopal et al., 2001) (Corbin et al., 2000) . PDE5 or PDE5 (80 l) isolated regulatory domain (4 nM final protein concentration in reaction mixture) was added to 2 ml of a mixture of 0.2 M [ 3 H]cGMP, 10 mM potassium phosphate, pH 6.8, 25 mM 2-mercaptoethanol, and 0.2 mg/ml Type II-AS histone (Sigma). After 45 min at 4°C, the sample was filtered onto premoistened Millipore filters (pore size, 0.45 m), which were then rinsed with 3 ml of 10 mM potassium phosphate, pH 6.8, and 25 mM ␤-mercaptoethanol, dried, and counted.
3 H Inhibitor Membrane Filtration-Binding Assay. Fulllength bovine His-tagged PDE5 (80 l) was added to 2 ml of a binding reaction mixture that contained 0.2 mg/ml histone IIA-S, various concentrations of 3 H inhibitor, and buffer that consisted of 10 mM potassium phosphate, pH 6.8, and 25 mM ␤-mercaptoethanol (KPM). Sticking of 3 H inhibitor to the sides of the test tube occurred when 3 H inhibitor was added in the absence of or before addition of histone. Histone also increased retention of PDE5 on the Millipore membranes. Binding reaction mixture containing the enzyme was incubated on ice or in a 30°C water bath for 45 min. Millipore nitrocellulose membranes (0.45 m) were placed under house vacuum and prewetted with 1 ml of ice-cold 10 mM potassium phosphate, pH 6.8, that contained 0.1% Triton X-100. Next, 200 l of 25% Triton X-100 at room temperature in KPM was added to the reaction tube. The entire contents of the tube were applied to the prewetted filter. The reaction tube was then washed with 3 ml of cold 0.1% Triton X-100 in 10 mM potassium phosphate, pH 6.8, and the wash was also applied to the filter. Filter membranes were removed, dried, and transferred to 6-ml scintillation vials. Nonaqueous scintillant (5 ml) was added to the tubes, which were then placed in a scintillation counter.
Statistical Analyses. All values are given as mean Ϯ standard error of mean (S.E.M.) as determined by GraphPad Prism graphics software (GraphPad Software Inc., San Diego, CA). The software uses the following equation: S.E.M. ϭ standard deviation/n 1/2 , where standard deviation is determined as [͚(y i Ϫ y mean ) 2 /(n Ϫ 1)] 1 ⁄2. All S.E.M. values reported fit within a 95% confidence interval, which quantifies the precision of the mean.
Results
Inhibition of PDE5 Catalytic Activity. The concentration of inhibitor that produces 50% inhibition of PDE5 catalytic activity (IC 50 ) was determined for each of the inhibitors (sildenafil, tadalafil, and vardenafil) using 0.4 M [ 3 H]cGMP as substrate (Fig. 1) . The IC 50 values were the following: sildenafil, 3.7 Ϯ 1.4 nM (n ϭ 4); tadalafil, 1.8 Ϯ 0.4 nM (n ϭ 7); and vardenafil, 0.091 Ϯ 0.031 nM (n ϭ 5). Similar values were obtained when using native bovine PDE5 (data not shown). These values agreed with the range of published IC 50 values [sildenafil, 1-9 nM (Ballard et al., 1998; Turko et al., 1999; ; tadalafil, 1-7 nM Gresser and Gleiter, 2002) ; and vardenafil, 0.1-0.8 nM (Saenz de Tejada et al., 2001; Gresser and Gleiter, 2002; ].
Stoichiometry of 3 H Inhibitor Binding to PDE5. The binding stoichiometry was determined for each inhibitor by dividing maximum binding (B max , picomoles of 3 H inhibitor binding per milliliter of PDE5) obtained from GraphPad Prism graphics, by PDE5 enzyme concentration (picomoles of PDE5 subunit per milliliter of PDE5). PDE5 protein concentration was determined by amino acid analysis. Stoichiometry was corrected for 75% recovery of 3 H inhibitor binding to PDE5 using the vacuum filtration method as determined previously . [ 3 H]Tadalafil bound to PDE5 with a stoichiometry of 0.68 Ϯ 0.10 mol/subunit (n ϭ 7), which was similar to the [ 3 H]vardenafil stoichiometry of 0.41 Ϯ 0.05 mol/subunit (n ϭ 8). These values compared well with the stoichiometry previously reported for [
3 H]sildenafil of 0.61 Ϯ 0.13 mol/subunit Fig. 3 . K D values, obtained by using nonlinear regression analysis with GraphPad Prism software, were as follows: sildenafil, 4.8 Ϯ 0.8 nM (n ϭ 3); tadalafil, 2.4 Ϯ 0.6 nM (n ϭ 4); and vardenafil, 0.38 Ϯ 0.07 nM (n ϭ 5). These values agreed well with the IC 50 values reported above.
Potencies for sildenafil, tadalafil, and vardenafil were also determined by competition studies. For example, Fig. 4 shows the effect of increasing concentrations of unlabeled vardenafil on binding of 3 nM [ 3 H]tadalafil. The EC 50 value was calculated from GraphPad Prism graphics software using a sigmoidal dose-response curve. Because EC 50 values were determined using a 3 H inhibitor concentration at the approximate K D value for PDE5, the Cheng and Prusoff/ Chou equation (Cheng and Prusoff, 1973; Chou, 1974) Table 2 ). The results indicated that the higher biochemical potency of vardenafil over sildenafil is caused by differences within the double rings of the two compounds.
Heterogeneity of the PDE5 Catalytic Domain Revealed by 3 H Inhibitor Dissociation Kinetics. Exchangedissociation kinetics of each of the 3 H inhibitors from PDE5 were examined. PDE5 was first saturated with 3 H inhibitor (30 nM), and aliquots were removed to determine 3 H inhibitor binding at 0 time. Unlabeled inhibitor (ϳ33,000-fold excess) was then added to the reaction mixture, and aliquots were removed for filtration at various times to follow the time course of dissociation (exchange) of the radiolabeled inhibitor from the enzyme. Under these conditions, the enzyme remained saturated at all times with inhibitor. All three inhibitors exhibited nonlinear dissociation kinetics indicative of the presence of at least two rate components (Fig. 5A) . In Fig.  5B , the x-axis was changed to emphasize the earlier time points. Assuming the presence of two components, when the line of the slower component was extrapolated to the y-axis, the calculated percentages of the two components were different for each inhibitor. Sildenafil, as reported previously, exhibited two equal components. The dissociation behavior of [ 3 H]tadalafil revealed 60% high-affinity (slow) and 40% lowaffinity (fast) components. [
3 H]Vardenafil dissociation exhibited 85% high-affinity and 15% low-affinity components. The overall rate of dissociation of [ 3 H]vardenafil was much slower than that of the other two inhibitors. After estimation of the t 1/2 for dissociation, the K D of each inhibitor was calculated from the following equation: K D ϭ 6.93 ϫ 10 Ϫ7 M ⅐ s/t 1/2 , where M ϭ molar, s ϭ seconds, and t 1/2 is measured in seconds. (Limbird, 1995) . All exchange-dissociation experiments were performed three times with each 3 H inhibitor. 3 H inhibitor binding at 30°C, which approaches physiological temperature. Increasing the temperature from 4°to 30°C had no effect or perhaps slightly inhibited sildenafil and tadalafil binding (data not shown). However, the increase in temperature increased vardenafil binding in the presence of cGMP, as is discussed below.
The effect of increasing cGMP concentrations on [ 3 H]vardenafil binding was carried out using 0.5 nM [ 3 H]vardenafil at both 4°and 30°C (Fig. 7) . At 4°C, [ 3 H]vardenafil showed a 2.5-fold increase in binding at low levels of cGMP (1-50 M), although this effect waned at higher cGMP concentrations. Repeating the experiment at 30°C with increasing cGMP produced a ϳ3.5-fold stimulation of [ 3 H]vardenafil binding to PDE5 at 30°C. The cGMP effect remained constant at moderate concentrations and waned slightly at very high cGMP concentration.
When binding using increasing concentrations of [ 3 H]vardenafil was performed at 30°C in the presence of constant 10 M cGMP, the labeled compound bound to PDE5 with a slightly higher affinity than at 4°C (0.42 Ϯ 0.06 nM, n ϭ 3, versus 0.59 Ϯ 0.02 nM, n ϭ 3). (Fig. 8, A and  B) .
The addition of 10 M cGMP to increasing concentrations of [
3 H]vardenafil at 4°C decreased the K D (0.74 Ϯ 0.10 nM, n ϭ 3, to 0.59 Ϯ 0.02 nM, n ϭ 3) while increasing the B max for PDE5 (5.63 Ϯ 0.38 to 6.58 Ϯ 0.10 pmol/ml) (Fig. 8A) . At 30°C, cGMP caused a 3.6-fold decrease in K D from 2.19 Ϯ 0.62 nM (n ϭ 3) to 0.42 Ϯ 0.06 nM (n ϭ 3), whereas the B max did not significantly change (4.93 Ϯ 0.71 versus 5.25 Ϯ 0.22 pmol/ml) (Fig. 8B) .
As shown in Fig. 9 , cGMP also stimulated binding of 3 nM [ 3 H]tadalafil at 4°C, and the effect was maximal at ϳ25 M cGMP. The stimulatory effect waned at higher cGMP concentrations in a manner similar to the cGMP effect on vardenafil binding at 4°C. The addition of 10 M cGMP to increasing concentrations of [ 3 H]tadalafil at 4°C decreased K D ϳ2-fold from 3.7 Ϯ 0.39 nM (n ϭ 3) to 1.74 Ϯ 0.05 nM (n ϭ 3), whereas the B max was 4.97 Ϯ 0.14 and 5.95 Ϯ 0.19 pmol/ml, respectively (Fig. 10) . The present report demonstrates that [ 3 H]tadalafil and [ 3 H]vardenafil are also specific for binding to the catalytic site. Binding of each of the three 3 H inhibitors was inhibited by catalytic site-selective agents and by unlabeled sildenafil, tadalafil, or vardenafil, suggesting that binding of each inhibitor is restricted to the catalytic domain and that all three inhibitors also bind to the same catalytic site. The stoichiometry of each 3 H inhibitor binding approached 1 mol/PDE5 subunit, which was consistent with inhibitor binding specifically to the catalytic site and also was indicative of one catalytic site per PDE5 monomer.
The isolated regulatory domain of PDE5 did not bind 3 H inhibitor using the same binding assay used for PDE5 holoenzyme even though the regulatory domain bound [ 3 H]cGMP nearly stoichiometrically. In addition, unlabeled sildenafil, tadalafil, or vardenafil did not compete with [ 3 H]cGMP for binding to the regulatory domain, confirming that these inhibitors do not bind to the regulatory domain. K D values determined by binding isotherms, EC 50 , or exchange-dissociation agreed with IC 50 of each inhibitor, again supporting the conclusion that the PDE5-specific inhibitors interact exclusively with the catalytic site of PDE5. Because cGMP-binding sites in the PDE5 regulatory and catalytic domains are evolutionarily and biochemically distinct, this result was not surprising.
This laboratory has used membrane vacuum filtration to measure [
3 H]cGMP binding (Francis and Corbin, 1988) , 65 Zn binding (Francis et al., 1994) , and [
3 H]sildenafil binding . This assay was modified slightly for specific [ 3 H]tadalafil and [ 3 H]vardenafil binding to PDE5. All three 3 H inhibitor binding assays produced high recoveries and yielded nearly 1 mol/subunit binding. Radiolabeled rolipram binding to PDE4 has been reported (Schneider et al., 1986; Torphy et al., 1992) ; however, the stoichiometry of Fig. 5 . Exchange-dissociation of 3 H inhibitor from PDE5. PDE5 (0.35 nM final concentration in assay) was added to 4.5 ml of binding reaction mixture containing 3 H inhibitor (30 nM final concentration). Then, to determine the zero time point, a 520-l aliquot of this mixture was filtered as described under Materials and Methods. Next, 30 l of a 1 mM solution of the corresponding unlabeled inhibitor was added to the remaining incubating binding reaction mixture at 4°C. Aliquots were removed and filtered by the same procedure at the indicated time points. A represents a longer time course, whereas B shows a shorter time course to emphasize curvilinear kinetics. Data represent three experiments, each performed in triplicate. binding in those studies was less than 0.01 mol/subunit using membrane filtration.
IC 50 values of sildenafil, tadalafil, and vardenafil determined here in head-to-head assays using bovine PDE5 were in the same range as IC 50 values reported in the literature using human PDE5 (Table 3) . Therefore, results are similar using recombinant PDE5, native PDE5, or PDE5 from different mammalian species. Whereas IC 50 is the classic method of determining potency (affinity) of PDE inhibitors, measurement of binding strength, or K D , is a more direct method of determining potency and it also provides a measure of stoichiometry of ligand binding. This report determined the potencies for sildenafil, tadalafil, and vardenafil using four separate head-to-head methods. IC 50 measurements yielded a potency ratio of 1:2:41, K D (binding isotherm) yielded a ratio of 1:2:13, K D ( 1 ⁄2 EC 50 ) yielded a ratio of 1:5:26, and K D (exchange-dissociation) yielded a ratio of 1:2:14 for sildenafil, tadalafil, and vardenafil, respectively (Table 3 ). This investigation represents the most comprehensive examination of the absolute and relative potencies of these drugs.
Dissociation rates of inhibitors from PDE5 correlated with potencies determined by IC 50 or isotherm K D , i.e., the slower the rate, the higher the potency. However, the faster dissociation rate of tadalafil from PDE5 compared with that of vardenafil may be unexpected in view of the longer lasting clinical effects of tadalafil. These clinical differences of tadalafil may be caused by pharmacokinetic considerations such as slower intestinal absorption or slower degradation by the liver, rather than by different biochemical properties.
In comparing the distinctive chemical structures of sildenafil and vardenafil, two major differences are evident: 1) a methyl group is appended to the piperazine ring of sildenafil, whereas the same ring in vardenafil has an appended ethyl group, and 2) a nitrogen atom is present in the 7-position of the double ring of sildenafil, but it is not present in the ring of vardenafil, although vardenafil contains a nitrogen atom in the 5-position, which is absent in sildenafil. To resolve which of these structural differences of the compounds determines potency, two analogs were synthesized: demethylvardenafil (analog of vardenafil containing the appended methyl group of sildenafil) and methyl-sildenafil (analog of sildenafil containing the appended ethyl group of vardenafil). Demethyl-vardenafil and vardenafil had almost identical IC 50 values, whereas methyl-sildenafil had 52-times higher IC 50, which was similar to the IC 50 of sildenafil. K D values obtained from EC 50 experiments using both analogs also indicated that methyl-sildenafil had much lower potency than either of the other two analogs. From these results, the higher biochemical potency of vardenafil compared with sildenafil is caused by differences within the double rings of the two compounds. The crystal structure of the PDE5 catalytic domain containing either sildenafil or vardenafil was reported recently (Sung et al., 2003) ; however, the resolution of the crystal structure was not sufficient to identify distinct interactions of either of these two inhibitors with the enzyme. The difference in the double ring of vardenafil, compared with sildenafil, may possibly allow for a stronger interaction between the compound and one or more of the amino acids (e.g., Tyr-612, Val-782, Phe-820, Leu-785, and Gln-817) that could be important for binding of the double ring of the inhibitor to human PDE5 (Sung et al., 2003) . In addition, the position of the nitrogen atom in the vardenafil double ring may impart a change in an atom or group of this molecule that provides contact with a residue that is not contacted by sildenafil or that provides an indirect contact resulting from change in the electron distribution in the double ring.
Exchange-dissociation experiments using each of the three 3 H inhibitors revealed curvilinear dissociation kinetics, suggesting the presence of two or more catalytic site components. There was an apparent link between inhibitor potency and percentage of high-affinity (slow) component of binding. This could mean that 1) the three 3 H inhibitors selected differently for binding to two preexisting populations of PDE5 having different affinities; 2) the inhibitors had different potencies for promoting conversion of one population into another; or 3) a combination of both mechanisms. Dissociation of 3 H inhibitor induced by infinite dilution also displayed heterogeneous kinetics. One possible explanation for the presence of two or more components of 3 H inhibitor dissociation is that PDE5 exists in different conformations . PDE2 (Manganiello et al., 1990 ) and PDE4 (Laliberte et al., 2000) also demonstrated kinetic heterogeneity, which was interpreted to represent different enzyme conformations. The present report is the first to extensively demonstrate that the PDE5 catalytic site exhibits more than one kinetic state, but whether or not it was caused by the presence of different PDE5 conformations remains to be proved. It cannot be ruled out that PDE5 undergoes partial modification during preparation, which could explain the heterogeneity observed, although the presence of two components is observed in different preparations of recombinant PDE5 and native PDE5. Regardless, caution must now be used in interpreting binding isotherm K D values that assume the presence of a single component in the calculation .
Cooperativity of inhibitor binding to PDE5 might occur if binding of inhibitors to the catalytic site of one of the two subunits affects binding to the other subunit. However, inhibitor dissociation after infinite dilution in the absence and presence of excess unlabeled inhibitor indicated that this is not the case, at least under the conditions used for the experiment.
Whereas the molecular mechanism for stimulation of PDE5 catalytic activity by cGMP binding to the regulatory domain is unknown, it is suggested that cGMP binding to this domain relieves PDE5 of an autoinhibitory constraint, at which point filling of the catalytic site at subsaturating substrate levels of cGMP is facilitated, increasing catalytic activity. This negative feedback mechanism promotes rapid degradation of cGMP within the cell. This negative feedback could be problematic for individuals with erectile dysfunction who are unable to maintain the high level of cGMP in the corpus cavernosum for the extended time that is required to achieve and maintain penile erection. This potential deficiency is apparently overcome by the presence of nonhydro- 
